P53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: A tissue microarray study

Modern Pathology

Volumn 18, Issue 12, 2005, Pages 1527-1534

  Tan, Puay Hoon ^a   Jayabaskar, Thiyagarajan ^b   Yip, George ^c   Tan, Yen ^a   Hilmy, Maryam ^a   Selvarajan, Sathiyamoorthy ^a   Bay, Boon Huat ^c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b National Kidney Foundation   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOTIN; PROTEIN P53; STEM CELL FACTOR RECEPTOR; STREPTAVIDIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; EPITHELIUM; EVALUATION; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MYOEPITHELIUM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STROMA; TISSUE MICROARRAY; TUMOR CLASSIFICATION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHYLLODES TUMOR; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27944442862     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800488     Document Type: Article

References (35)

1. Feakins RM, Mulcahy HE, Nickols CD, et al. p53 expression in phyllodes tumors is associated with histological features of malignancy but does not predict outcome. Histopathology 1999;35:162-169.
2. Keelan PA, Myers JL, Wold LE, et al. Phyllodes tumor: clinicopathologic review of 60 patients and flow cytometric analysis in 30 patients. Hum Pathol 1992;23:1048-1054.
3. Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumors of the breast by PCR-based clonality assay. J Pathol 2002;197:575-581.
4. Noguchi S, Yokouchi H, Aihara T, et al. Progression of fibroadenoma to PT demonstrated by clonal analysis. Cancer 1995;76:1779-1785.
5. Zurrida S, Bartoli C, Galimberti V, et al. Which therapy for unexpected phyllode tumor of the breast. Eur J Cancer 1992;28:654-657.
6. Moffat CJC, Pinder SE, Dixon AR, et al. Phyllodes tumors of the breast: a clinicopathological review of thirty-two cases. Histopathology 1995;27:205-218.
7. Reinfuss M, Mitus J, Smolak K, et al. Malignant phyllodes tumors of the breast. A clinical and pathological analysis of 55 cases. Eur J Cancer 1993;29A:1252-1256.
8. Reinfuss M, Mitus J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast. An analysis of 170 cases. Cancer 1996;77:910-916.
9. Chaney AW, Pollack A, Mcneese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000;89:1502-1511.
10. Hawkins RE, Schofield JB, Fisher C, et al. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer 1992;69:141-147.
11. Cohn-Cedermark G, Rutqvist LE, Rosendahl I, et al. Prognostic factors in cystosarcoma phyllodes. A clinicopathologic study of 77 patients. Cancer 1991;68:2017-2022.
12. Pietruszka M, Barnes L. Cystosarcoma phyllodes. A clinicopathologic analysis of 42 cases. Cancer 1978;41:1974-1983.
13. Barth Jr RJ. Histologic features predict local recurrence after breast conserving therapy of PT. Breast Cancer Res Treat 1999;57:291-295.
14. Kleer CG, Giordano TJ, Braun T, et al. Pathologic, immunohistochemical, and molecular features of benign and malignant PT of the breast. Mod Pathol 2001;14:185-190.
15. Tan PH, Jayabaskar T, Chuah KL, et al. Phyllodes tumors of the breast. The role of pathologic parameters. Am J Clin Pathol 2005;123:529-540.
16. Kuenen-Boumeester V, Henzen-Logmans SC, Timmermans MM, et al. Altered expression of p53 and its regulated proteins in phyllodes tumors of the breast. J Pathol 1999;189:169-175.
17. Tse GMK, Putti TC, Kung FYL, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 2002;15:734-740.
18. Millar EKA, Beretov J, Marr P, et al. Malignant phyllodes tumors of the breast display increased stromal p53 protein expression. Histopathology 1999;34:491-496.
19. Niezabitowski A, Lackowska B, Rys J, et al. Prognostic evaluation of proliferative activity and DNA content in the PT of the breast: immunohistochemical and flow cytometric study of 118 cases. Breast Cancer Res Treat 2001;65:77-85.
20. Sawyer EJ, Poulsom R, Hunt FT, et al. Malignant phyllodes tumors show stromal overexpression of c-myc and c-kit. J Pathol 2003;200:59-64.
21. Chen CM, Chen CJ, Chang CL, et al. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res 2000;94:84-91.
22. Tan Y, Hilmy MH, Hung H, et al. Initial experience with tissue microarray (TMA) in a surgical pathology laboratory: technical considerations. The J Histotechnol 2004;27:113-117.
23. Tan PH, Ho GH, Ji CY, et al. Immunohistochemical expression of p53 protein in invasive breast carcinoma: clinicopathologic correlations. Oncol Rep 1999;6:1159-1163.
24. Gatalica Z, Finkelstein S, Lucio E, et al. p53 protein expression and gene mutation in phyllodes tumors of the breast. Pathol Res Pract 2001;197:183-187.
25. Tse GM, Lui PC, Scolyer RA, et al. Tumor angiogenesis and p53 protein expression in mammary phyllodes tumors. Mod Pathol 2003;16:1007-1013.
26. Dacic S, Kounelis S, Kouri E, et al. Immunohistochemical profile of cystosarcoma phyllodes of the breast: a study of 23 cases. Breast J 2002;8:376-381.
27. Witte F, Honig A, Mirecka J, et al. Cystosarcoma phyllodes of the breast: prognostic significance of proliferation and apoptosis associated genes. Anticancer Res 1999;9:3355-3360.
28. Sawyer EJ, Hanby AM, Ellis P, et al. Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. Am J Pathol 2000;156:1093-1098.
29. Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 2004;61:2924-2931.
30. Hornick JL, Fletcher CD. Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 2003;119:325-327.
31. Carvalho S, e Silva AO, Milanezi F, et al. c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? J Clin Pathol 2004;57:1075-1079.
32. Woolley PV, Gollin SM, Riskalla W, et al. Cytogenetics, immunostaining for fibroblast growth factors, p53 sequencing, and clinical features of two cases of cystosarcoma phyllodes. Mol Diagn 2000;5:179-190.
33. Silverman JS, Tamsen A. Mammary fibroadenoma and some phyllodes tumor stroma are composed of CD34+ fibroblasts and factor XIIIa+ dendrophages. Histopathology 1996;29:411-419.
34. Zhang D, Salto-Tellez M, Putti TC, et al. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003;16:79-84.
35. Shergill IS, Shergill NK, Arya M, et al. Tissue microarrays: a current medical research tool. Curr Med Res Opin 2004;20:707-712.